Saved in:
| Main Author: | |
|---|---|
| Format: | Preprint |
| Published: |
2025
|
| Subjects: | |
| Online Access: | https://arxiv.org/abs/2503.15418 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866917962076651520 |
|---|---|
| author | Shan, Minghua |
| author_facet | Shan, Minghua |
| contents | Tumor response, a binary variable, has historically been the main measure of antitumor activity for many cancer phase II single-arm trials. Simon two-stage designs are often used. Sargent et al. proposed a three-outcome trial design in this setting which requires smaller sample sizes. For many new, molecularly targeted therapies, however, tumor response may not be the most reliable endpoint for measuring anti-tumor activity. Increasingly, time-to-event endpoints, such as progression-free survival (PFS), are used in the phase II setting. When such endpoints are the primary measure of efficacy, a randomized concurrently controlled study design is usually required. Given limited resources for phase II, studies are often underpowered with relatively large type I and II error rates, and it is sometimes unavoidable to have a "gray" decision zone after phase II where a clear decision regarding further development actions cannot be made without additional information. Compared with an underpowered standard two-outcome study, a three-outcome design prompts clinical trialists to contemplate the likelihood of landing in the "gray" zone at the trial design stage and choose study design parameters more appropriately. We propose a three-outcome design, with or without interim analyses, for randomized comparative phase II trials when a time-to-event endpoint is used. |
| format | Preprint |
| id |
arxiv_https___arxiv_org_abs_2503_15418 |
| institution | arXiv |
| publishDate | 2025 |
| record_format | arxiv |
| spellingShingle | A time-to-event three-outcome design for randomized phase II cancer trials Shan, Minghua Methodology Tumor response, a binary variable, has historically been the main measure of antitumor activity for many cancer phase II single-arm trials. Simon two-stage designs are often used. Sargent et al. proposed a three-outcome trial design in this setting which requires smaller sample sizes. For many new, molecularly targeted therapies, however, tumor response may not be the most reliable endpoint for measuring anti-tumor activity. Increasingly, time-to-event endpoints, such as progression-free survival (PFS), are used in the phase II setting. When such endpoints are the primary measure of efficacy, a randomized concurrently controlled study design is usually required. Given limited resources for phase II, studies are often underpowered with relatively large type I and II error rates, and it is sometimes unavoidable to have a "gray" decision zone after phase II where a clear decision regarding further development actions cannot be made without additional information. Compared with an underpowered standard two-outcome study, a three-outcome design prompts clinical trialists to contemplate the likelihood of landing in the "gray" zone at the trial design stage and choose study design parameters more appropriately. We propose a three-outcome design, with or without interim analyses, for randomized comparative phase II trials when a time-to-event endpoint is used. |
| title | A time-to-event three-outcome design for randomized phase II cancer trials |
| topic | Methodology |
| url | https://arxiv.org/abs/2503.15418 |